These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7715078)

  • 1. [Hypoplastic leukemia achieved long-term remission with low-dose cytosine arabinoside].
    Fujisawa S; Kanamori H; Noguchi T; Maruta A; Ogawa K; Sakai R; Taguchi J; Tomita N; Kodama F; Okubo T
    Rinsho Ketsueki; 1995 Jan; 36(1):56-8. PubMed ID: 7715078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
    Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
    Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of low-dose Ara-C regimen on myelodysplastic syndrome (MDS)].
    Kuriyama K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1198-204. PubMed ID: 3164177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
    Tsukaguchi M; Furukawa Y; Kitani T
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1603-7. PubMed ID: 9725056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
    Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
    Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of low dose Ara-C regimen in acute leukemias and RAEB].
    Kohno T; Nagai K; Tsukazaki K; Jinnai I; Tomonaga M; Ichimaru M; Tagawa M
    Rinsho Ketsueki; 1989 May; 30(5):638-43. PubMed ID: 2795877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P; Vítek A; Jelínek J; Lukásová M; Palecek A; Sajdová J; Jedlicková A; Vorlová Z
    Vnitr Lek; 1995 Jan; 41(1):34-9. PubMed ID: 7716891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [RAEB in transformation in continuing complete remission by small doses of cytarabin].
    Yamada T; Sueoka N; Tanabe Y; Dan K; Kuriya S; Nomura T; Shiomura T
    Rinsho Ketsueki; 1989 Mar; 30(3):371-5. PubMed ID: 2769960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypoplastic leukemia successfully treated with low-dose aclarubicin: a case report].
    Toyota E; Ohtsuki T; Kamiyama N; Fukushima T; Shirato L; Kanzaki A; Yamada O; Yawata Y
    Rinsho Ketsueki; 1991 Sep; 32(9):996-1000. PubMed ID: 1942547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute leukemia in the elderly--a death sentence?].
    Zeidman A; Yarmolowski A; Mittelman M
    Harefuah; 1994 Jul; 127(1-2):1-3, 64. PubMed ID: 7959377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.